Hardy v. Hamburg
Decision Date | 23 September 2014 |
Docket Number | Civil Action No. 11–1739 RBW |
Citation | 69 F.Supp.3d 1 |
Court | U.S. District Court — District of Columbia |
Parties | Paul T. Hardy, et al., Plaintiffs, v. Margaret A. Hamburg, et al., Defendants. |
David K. Colapinto, Stephen M. Kohn, Kohn, Kohn & Colapinto, LLP, Washington, DC, for Plaintiffs.
Andrew L. Nolan, W. Scott Simpson, Thomas David Zimpleman, U.S. Department of Justice, Washington, DC, for Defendants.
The plaintiffs, six former and current employees of the Food and Drug Administration (“FDA”), filed this civil lawsuit against the defendants, Margaret A. Hamburg, the Commissioner of the FDA; the FDA; Kathleen Sebelius, the Secretary of the Department of Health and Human Services (“DHHS”); the DHHS; Regina Benjamin, the Surgeon General of the Public Health Service (“Public Health Service”); and the Public Health Service, alleging violations of the First, Fourth, and Fifth Amendments of the Constitution and the Lloyd–LaFollette Act. Second Amended Complaint (“Am.Compl.”) ¶¶ 127–97. Currently before the Court is the Defendants' Motion to Dismiss for lack of subject-matter jurisdiction () . After carefully considering the parties' submissions,1 the Court concludes that it must grant the motion to dismiss for the reasons set forth below.
The passage of the Civil Service Reform Act of 1978 (“CSRA”), Pub.L. No. 95–454, 92 Stat. 1111 ( ), established a comprehensive framework for federal employees to have “prohibited personnel practices” of agencies reviewed and remedied administratively.2 5 U.S.C. § 2302 (2012) ; see also United States v. Fausto, 484 U.S. 439, 445–49, 108 S.Ct. 668, 98 L.Ed.2d 830 (1988) ( ). The Whistleblower Protection Act of 1989 subsequently “amend[ed] the list of prohibited personnel practices under the framework of the CSRA” to include reprisals for whistleblower activity. Heard v. U.S. Dep't of State, No. 08–cv–02123(RBW), 2010 WL 3700184, at *6 n. 7 (D.D.C. Sept. 17, 2010) (Walton, J.); see also 5 U.S.C. § 2302(b)(8). “A federal employee who alleges unlawful retaliation for whistleblowing must first bring his claim to the Office of Special Counsel.” Heard, 2010 WL 3700184, at *6 (citing 5 U.S.C. § 1214 and Weber v. United States, 209 F.3d 756, 757–58 (D.C.Cir.2000) ). “If the [Office of Special Counsel] finds an absence of wrongdoing, the employee can appeal that decision to the Merit Systems Protection Board, 5 U.S.C. §§ 1214(a)(3), 1221.” Id. Without exhausting these administrative remedies, this Court lacks jurisdiction.3 Weaver v. U.S. Info. Agency, 87 F.3d 1429, 1433 (D.C.Cir.1996) (); Heard, 2010 WL 3700184, at *6 n. 7 (Walton, J.) .
“The [p]laintiffs are a group of six doctors and scientists” who have made public statements about the allegedly “serious managerial and medical misconduct within the [FDA's] Center for Devices and Radiological Health,” which is “the unit within the FDA with the responsibility to review and approve the use of medical devices.” Pls.' Opp'n at 1; see also Am. Compl. ¶¶ 15, 17, 19, 72. Doctor (“Dr.”) R. Lakshmi Vishnuvajjala and Nancy G. Wersto are current employees of the FDA. Am. Compl. ¶¶ 7, 8. The other plaintiffs are not. Id. ¶¶ 3–6. Dr. Ewa M. Czerska and Dr. Robert C. Smith are both former employees of the FDA. I d. ¶¶ 4, 5. Paul T. Hardy is a former officer of the Public Health Service Commissioned Corps. Id. ¶ 3; Pls.' Opp'n at 2. During his tenure as an officer in the Public Health Service Commissioned Corps, Mr. Hardy was assigned to work for the FDA. Am. Compl.
¶ 118; Pls.' Opp'n at 2. Dr. Julian Nicholas is a “former federal contractor, [who] work[ed] for the FDA through the Oak Ridge Institute for Science and Education ... program.” Am. Compl. ¶ 6; Pls.' Opp'n at 2.
Beginning no later than November 2008, the plaintiffs began “rais[ing] significant health and safety concerns regarding the FDA's regulatory review and clearance/approval of [allegedly] unsafe and ineffective medical devices.” Pls.' Opp'n at 3; Am. Compl. ¶¶ 15, 17, 46–58, 72. The plaintiffs also alleged that FDA doctors and scientists had been “intimidated and coerced” into “modify[ing] their scientific reviews, conclusions[,] and recommendations in violation of law.” Pls.' Opp'n at 4 (internal quotations omitted); Am. Compl. ¶ 15. “These concerns were raised both inside and outside the FDA, and were specifically raised with [m]embers of Congress, [then] President-elect Barack Obama's [t]ransition [t]eam, [then-] President[-elect Barack] Obama, and representatives of the news media.” Pls.' Opp'n at 3; Am. Compl. ¶¶ 15, 17, 19, 46–58, 72.
For example, in November 2008, several of the plaintiffs Mr. Hardy, Dr. Czerska, Dr. Smith, and Ms. Wersto—“were among a group of FDA scientists who” informed “the House Energy and Commerce Committee about [alleged] managerial misconduct in the FDA.” Am. Compl. ¶ 15. Similarly, in January 2009, Mr. Hardy, Dr. Czerska, Dr. Smith, and Ms. Wersto joined five other FDA employees to sign and send a letter to then President-elect Barack Obama's transition team that “raised numerous issues of public concern, including [alleged] corruption within the FDA's device review process, managerial misconduct, dangers to public health and welfare, and retaliation against whistleblowers.” Id. ¶ 17. The FDA learned of the letter and its nine signatories, and began allegedly referring to those “signatories as the ‘FDA 9.’ ” Id. ¶ 18. Later that same year, in September 2009, “a group of FDA whistleblowers, including Dr. Nicholas ... and Dr. Smith,” continued to “sp [eak] with members of the House Energy and Commerce Committee” about “their concerns regarding” the FDA's review and approval of allegedly unsafe and ineffective medical devices. Id. ¶ 58. The following year, in March 2010, the New York Times published an article concerning the plaintiffs—“the FDA whistleblowers”—and their warnings to the FDA about its approval of allegedly “ineffective and dangerous devices and ignoring or suppressing the concerns of its own scientists.” Pls.' Opp'n at 4; Am. Compl. ¶¶ 72–75.
“Sometime between January 2009 and March 2010,” under the auspices of the DHHS, the FDA allegedly “commenced ‘[t]argeted [s]urveillance’ ” on the plaintiffs in response to their whistleblower activities. Pls.' Opp'n at 5–8; id. at 6 (); Am. Compl. ¶¶ 21–45. According to the plaintiffs:
“Targeted [s]urveillance” was conducted on the plaintiffs (and other similarly situated FDA employees) because these employees were identified as whistleblowers, i.e.[,] employees who raised health and safety concerns and allegations of official misconduct that were protected under federal law and the United States Constitution. Employees [were] selected for [t]argeted [s]urveillance based on the viewpoint of their speech, and specifically because these employees have, or are suspected of having, criticized the FDA to Members of Congress, the news media or appropriate law enforcement agencies.
Id. ¶ 28; see also id. ¶¶ 26, 33, 99. The plaintiffs further allege that “ ‘[t]argeted [s]urveillance’ is distinct from ‘routine’ system monitoring of employee emails, for which the FDA and HHS also conduct.” Id. ¶ 27. They also contend that:
Pursuant to its [t]argeted [s]urveillance operation, the FDA secretly installed or activated spyware on the government-owned computers, hardware, and networks used by the [p]laintiffs. The spyware took real-time pictures, or “screen shots” (a.k.a. “snapshot recordings”) of the computer screens being used by the [p]laintiffs, while the [p]laintiffs were using the computers or networks. These screen shots enabled FDA officials to secretly view information that appeared on each of the [p]laintiffs' computer screens, even if the information was transitory and not stored within the computer itself.
Further, the plaintiffs allege that using “targeted surveillance,” the FDA acquired “confidential and/or privileged work product, tactics and strategy that the [p]laintiffs were using or planning to use as a result of [the] FDA intercepting [p]laintiffs' [p]rivate [e]-mail communications with” third parties including “private attorneys” and “other proper authorities.”4 Id. ¶ 40; see also id. ¶¶ 42–44 ( ); Pls.' Opp'n at 11–12.
In addition to “[t]argeted surveillance,” the plaintiffs represent that the defendants took several “other retaliatory actions ” against the plaintiffs for their whistleblower activities. Am. Compl. ¶ 126 (emphasis added); id. ¶¶ 30, 158, 160, 164, 165, 169, 170, 196. For example, the plaintiffs contend that several of the plaintiffs found themselves unemployed as a “direct result” of their whistleblower activities. Pls.' Opp'n at 9–10 (...
To continue reading
Request your trial-
Tabaddor v. Holder
...“pre-enforcement attack on a regulation restricting employee speech.” Weaver, 87 F.3d at 1434 ;4 see also Hardy v. Hamburg, 69 F.Supp.3d 1, 16–18 (D.D.C.2014).Defendants also contend that it does not matter, for CSRA preclusion purposes, that Plaintiff's First Amendment claims are framed as......
-
Elhelbawy v. Pritzker
...Ryan v. Donley, 511 F. App'x 687, 690 (10th Cir.), cert. denied, 134 S. Ct. 255 (2013) (citations omitted). See also Hardy v. Hamburg, 69 F. Supp. 3d 1, 12 (D.D.C. 2014) ("[u]nder no circumstances does the [CSRA, as amended by the Whistleblower Protection Act,] grant . . . [a] District Cour......
-
Lamb v. Holder
...bar this Court's jurisdiction to address the plaintiff's constitutional claims”); see also Hardy v. Hamburg, No. 11–cv–1739 (RBW), 69 F.Supp.3d 1, 23, 2014 WL 5420037, at *17 (D.D.C. Sept. 23, 2014), Coleman v. Napolitano, No 13–cv–1307 (BAH), 65 F.Supp.3d 99, 104–06, 2014 WL 4185190, at *4......
-
Manning v. McDonald, Case No. 3:16-cv-00706
...nature of the CSRA precludes certain judicial review of personnel actions other than as provided by the statute). 8. Hardy v. Hamburg, 69 F. Supp. 3d 1, 6 (D.D.C. 2014); see also 5 U.S.C. § 2302(b)(8). 9. Weaver, 87 F.3d at 1433; see also Heard v. U.S. Dep't of State, No. CIV.A. 08-02123 RB......